Maria Chiara Sighinolfi

From #livesurgery @ERUSrobotics in Düsseldorf to a Sunday #roboticsurgery session in Milan... 🤩

Surgical Technique and Perioperative and Postoperative Outcomes for Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Performed with the Hugo RAS Robotic Platform: First Large Case Series by the European Association of Urology Robotic Urology Section Scientific Working Group sciencedirect.com/science/articl… Multicentre study evaluated robot-assisted radical cystectomy using the Hugo RAS robotic platform in 29 patients undergoing lymph node dissection and intracorporeal urinary diversion. Surgical outcomes demonstrated acceptable operative times, hospital stay, and complication rates comparable to established robotic systems. Despite early adoption, the platform required no procedure-specific modifications, supporting its safety and feasibility and suggesting Hugo RAS represents a viable alternative for complex robotic #BladderCancer surgery. @SimoneScuderi1 @juhana_rautiola @MariaChiaraMCS @francprata @Ruben_De_Groote @EdwLambert @joanfundi @agallioli @BasileG_ @donatocann @UFalagario @GGandaglia @Albert0Briganti @F_Montorsi @RoccoPapaliaUro @oloakr @bernardorocco73 @alexmottrie @_alelarcher @AlbertoBreda1

Liquid biopsy is moving from exploratory tool to biological risk modifier in non‑metastatic prostate cancer, with ultra‑sensitive ctDNA emerging as the most promising approach for MRD detection and treatment tailoring #ProstateCancer #LiquidBiopsy #ctDNA #UroOnc @MariaChiaraMCS

@RicBertolo @EurUrolOncol @minerviniandre @PaoloVerze @antopastl @lucacindolo @foxal72 @EAU_Uroonco @aleantonellibs1 @AgileGroupUro 1) major prostate RT randomized trials report late toxicity rates but rarely mention salvage cystectomy for radiation damage. 2) PACE-A reports suboptimal results compared with current standards. Bottom line: study methodology must address data quality, not only trial design.

Excited to announce the inaugural International Uro-Onco Case Discussion Series — a new collaboration between @CleClinicUro & @PoliclinicoGem 🇺🇸🤝🇮🇹 🗓️ Nov 10 | 6:30AM EST / 12:30PM CET 🎯 Focus: #ProstateCancer @drjkaouk @bernardorocco73 @RubenOlivaresG @MariaChiaraMCS

Robotic-assisted cystectomy strategies: 🔬 21 expert surgeons analyzed 🤖 Demanding ileourethral approximation: 86% 🏗️ Studer/Bordeaux reconstructions popular 📉 Trendelenburg reduction: 43% #Urology #RARC #Neobladder #Pub2Post tinyurl.com/4kethxyf @MariaChiaraMCS @bernardorocco73 @Uroweb

#UROFEM25 Join us in Milan, Live surgeries by top female urologists & panels challenging stereotypes. Let’s celebrate urological excellence and inspire the next gen! @SeccoSilvia @FrancoGaboardi @MariaJRibal bit.ly/ProgramUROFEM25 bit.ly/RegistrationUR…

Relationship Between Undetectable PSA Nadir and Outcomes for Patients with #mHSPC in #IRONMAN, the International Registry for Men with Advanced #ProstateCancer. Undetectable PSA Nadir Predicts Better Outcomes in mHSPC 🔹 IRONMAN registry real-world data shows: ✅ 51% (6mo) & 63% (12mo) of ADT+ARPI patients hit PSA <0.2 ng/mL ✅ Achieving PSA <0.2 ng/mL at 6mo linked to lower relapse across all treatments ✅ Relapse-free survival lower with ADT+Docetaxel, but OS similar across groups 💡 Takeaway: Early PSA suppression is a key prognostic marker in mHSPC! Presentation by @hannahdzmd @DukeCancer. #GU25 written coverage by @chavarriagaj @UofT > bit.ly/4hCd4qT

On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily @urotoday

📢 7-8 marzo vi aspetto a #Holita, il congresso dedicato ai laser in urologia ! 18 live surgery #IPB e #calcolosi dal Policlinico di Tor Vergata. 📍Iscrizioni partnergraf.it @SIU_Italia @RegioneLazio @ptvonline2001 @unitorvergata #Holita #IPB #Calcolosi #Holep

A simple summary with the most updated results from the phase 3 trials with available IO-combos in mRCC after #GU25. @OncoAlert @urotoday @GUOncologyNow @urofocus @SIU_Italia @siuroIT

A new meta-analysis published this month in Annals suggests that patients treated by female surgeons have lower mortality than those treated by male surgeons. journals.lww.com/annalsofsurger…

🌟New #SpecialIssue “Advances in the Management of Pelvic Tumors” edited by Dr. Giorgia Gaia and Dr. Maria Chiara Sighinolfi is #openforsubmissions! @MariaChiaraMCS @ASST_PaoloCarlo ⏰Deadline for manuscript submissions: 1 September 2025 🔗More details: mdpi.com/journal/cancer…

Great to meet many colleagues during Serbia Urology Meeting @UrowebESU complications management session! Many Q&A from the audience during case discussion. Thanks very much for the invitation! @evanliats @MariaChiaraMCS @Uroweb @bernardorocco73 @TheodorosTokas

“Scratching” our abstract during @icsoffice, like a DJ. #ICS2024 #MyICS

🎤 Dünyanın dört bir yanından uzmanlar 33. Ulusal Üroloji Kongresi'nde buluşuyor! 🌍 Bilim, bilgi ve deneyim paylaşımı için geri sayım başladı. 📅 29 Ekim - 1 Kasım 📍 Antalya 🇺🇸 🇮🇹 🇶🇦 🇺🇸 🇬🇷 🇬🇧 🇬🇧 🇫🇷 🇮🇹 🇮🇹 🇮🇹 🇵🇱 🇲🇽 🇪🇸 🇦🇹 🇷🇸 🇪🇬 🇮🇹 🇧🇦 🇽🇰 🇦🇿 🇽🇰 🇲🇰 🇬🇷 🇦🇱 🇬🇷 #UlusalÜroloji24

Fluorine-18 PSMA-1007 PET/CT vs Multiparametric MRI for Prostate Cancer Staging 🔵Tumor Stage: 18F-PSMA-1007 PET/CT superior (45% vs 28%) 🔵Dominant Nodule: PET/CT better (94% vs 83%) 🔵Laterality: PET/CT better (64% vs 44%) 🔵ECE: PET/CT better (75% vs 63%) 🔵SVI: Not significantly different (91% vs 85%) 18F-PSMA-1007 PET/CT superior for locoregional staging. Supports its use in preoperative planning for intermediate/high-risk prostate cancer. @OncoAlert #cancer #oncology @JAMAOnc @Uroweb @PCFnews jamanetwork.com/journals/jamao…

Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent PCs Death—Results from the Norwegian Prostate Cancer Consortium by Johan Bjerner et al. Read the full article here: buff.ly/45B4T9m @bratt_ola @kirstiaas @VickersBiostats @SigridCarlsson

📢 Nuova possibilità di cura per pazienti affetti da tumore vescicale muscolo infiltrante eleggibili a chirurgia. Prima evidenza di come l'immunoterapia ⬆️ la sopravvivenza insieme alla chemioterapia! ✅️ astrazeneca.com/media-centre/p… @AssPalinuro

Probably an outdated discussion, but our randomized trial Open versus RARP was finally published. A Herculean effort that started 10 years ago

Independent blinded validation of an AI-based digital histology classifier (PATHOMIQ_PRAD score) for BCR and mets risk prediction #ASCO24 @MagdaFayMD @urotoday @CleClinicUro ⚡️n=263 RP (mF/U 50 mo) -> 65 BCR -> 14 distant mets ⚡️PATHOMIQ_PRAD score ⬆️ vs ⬇️: assoc with BCRFS (p<0.0001) and MFS (p<0.0001) ⚡️Decipher GC score ⬆️ vs ⬇️: assoc with BCRFS (p=0.0009) and MFS (p=0.0095)